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prior IV CDV exposure. Median BCV treatment duration 54
days (range: 1 to 108). Suppression of plasma AdV VL to <
LOD by quantitative PCR was 61% (14/23) at any time on-
treatment and 52% (12/23) at last on-treatment value.
Median change in plasma AdV VL from BL to nadir was
-1.4 log10 c/mL (range: -8.0 to 0.6), with 65% (15/23)
achieving  3 log10 decrease to nadir (or to < LOD). In-
dividual plots of plasma AdV VL over time are shown in
the ﬁgure. In subjects with positive qualitative AdV PCR at
BL, 42% (5/12) cleared AdV in respiratory secretions, 33%
(5/15) in urine and 27% (4/15) in stool. Six of the 11
subjects with prior IV CDV achieved AdV VL < LOD and
one had > 2 log10 decline at last on-treatment value.
Treatment-related AEs requiring premature BCV dis-
continuation were limited to severe diarrhea (in two
subjects). Among the 48 subjects enrolled through
19SEP2014, there were 17 deaths, including two of seven
subjects with asymptomatic disease (29%), in 11 of 29 allo
HCT subjects with disseminated AdV (38%) and four of 12
subjects with non-allo HCT disseminated AdV (33%), rep-
resenting an overall mortality rate to-date of 35% (17/48),
with a median duration of observation of 57 days for
living pts. Safety and efﬁcacy data from newly enrolled
subjects will be included in the presentation.
Conclusions: These preliminary results from 26 subjects
enrolled in the pilot portion of AdVise show mortality
rates of < 40% across subjects with limited and dissemi-
nated AdV and across populations with varying identiﬁed
risk factors (HCT, SOT, other); these are lower mortality
rates than those in the literature for disseminated disease.
AdV viremia was suppressed to undetectable in over half
of enrolled subjects. No new safety concerns were iden-
tiﬁed in this complex patient population. These data
support progression to deﬁnitive Phase 3 BCV study for
AdV.
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Introduction: Severe hepatic veno-occlusive disease (VOD,
also called sinusoidal obstruction syndrome) with multi-
organ failure (MOF) is a life-threatening complication of
hematopoietic stem cell transplant (HSCT), with a mor-
tality rate of >80%. Deﬁbrotide has a protective effect on
injured endothelium and restores thrombo-ﬁbrinolytic
balance. In severe VOD, deﬁbrotide improves complete
response (CR) rates and survival at Day+100 post-HSCT,
with a favorable safety proﬁle. In the EU, deﬁbrotide is
approved for treatment of severe hepatic VOD in HSCT
therapy in adults and children. In the US, there are no
approved therapies for VOD; however, deﬁbrotide is
available through an expanded access, protocol-directed
treatment IND (T-IND). The T-IND gathers data on safety/
efﬁcacy of deﬁbrotide in patients (pts) with severe and
non-severe VOD post-HSCT, as well as post-chemotherapy
(CT) alone.
Methods: The original T-IND protocol required VOD diag-
nosed by Baltimore criteria (total bilirubin 2.0 mg/dL
with 2 of hepatomegaly, ascites, or 5% weight gain)
with MOF (renal and/or pulmonary failure) following HSCT;
the study was amended to include non-severe VOD (deﬁned
as no MOF) post-HSCT or post-CT. Exclusion criteria include
clinically signiﬁcant bleeding or need for >1 vasopressor.
Deﬁbrotide was given as a 2-hour infusion at 6.25 mg/kg IV
q6h (25 mg/kg/d) for a recommended 21 days.
Results: This interim safety analysis update is based on 612
pts enrolled from December 2007 to December 2013
(including 99 in 2013) who received 1 deﬁbrotide dose.
Median patient age was 12 years (range <0.1e69).
Overall, 1 treatment emergent adverse event (AE) was
reported in 454 pts (74.2%). Of these, 138 pts (22.5%) had AEs
possibly, probably, or deﬁnitely related to deﬁbrotide.
Related AEs in >2.0% included pulmonary hemorrhage
(4.7%), gastrointestinal hemorrhage (3.6%), epistaxis (3.1%),
and hypotension (2.8%). Serious AEs (SAEs) were reported by
368 pts (60.1%) and most were assessed as not related to
deﬁbrotide; 82 pts (13.4%) had an SAE at least possibly
related to study treatment, most commonly pulmonary
hemorrhage (3.9%) and gastrointestinal hemorrhage (2.9%).
AEs leading to death occurred in 254 pts (41.5%); these AEs
were deemed possibly related to study medication in only 17
pts (2.8%).
Previously reported efﬁcacy data at Day+100 in 425
evaluable pts showed survival of 55% (by Kaplan-Meier
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mate) in 45 pts following CT.
Conclusions: Deﬁbrotide in pts with VOD was generally well
tolerated in this population, with manageable toxicity and
promising response rates and survival. Safety results from
prior studies are consistent with the favorable tolerability
proﬁle seen in this largest experience to date. Enrollment to
the T-IND study continues, with updated results to be pre-
sented at the meeting.
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Introduction: Hepatic veno-occlusive disease (VOD) is a
serious complication of hematopoietic stem cell trans-
plantation (HSCT) and, in severe cases, is associated with
multi-organ failure and mortality rates exceeding 80%. In the
US there are currently no FDA-approved treatments for se-
vere VOD. Deﬁbrotide, an oligonucleotide with a mechanism
of action that encompasses both restoration of the thrombo-
ﬁbrinolytic balance and endothelial cell protection, has
recently been approved for the treatment of severe VOD
following HSCT in the EU. The data presented are based on
the primary and secondary endpoint analyses provided to
the European Medicines Agency (EMA) that formed the basis
of the deﬁbrotide approval in the EU.
Methods: A pivotal phase 3 study examined the efﬁcacy and
safety of deﬁbrotide 25 mg/kg/day in patients with severe
VOD (n¼102) compared to historical controls (n¼32). The
study’s primary endpoint was complete response (CR) (in
terms of improvements in total bilirubin and resolution of
multi-organ failure measured by renal and/or pulmonary
dysfunction) by 100 days post-HSCT; secondary endpoints
included survival 100 days and 180 days post-HSCT. We
calculated the number needed to treat (NNT) with deﬁbro-
tide to achieve one complete response and the NNT to pre-
vent one death 100 days post-HSCT in patients with severe
VOD compared to historical controls who did not receive
deﬁbrotide in order to evaluate how deﬁbrotide compared to
other efﬁcacious treatments for acute, life-threatening con-
ditions. NNT is calculated as the reciprocal of the absolute
risk reduction (1/ARR), where ARR is equal to the control
minus experimental event rates.
Results: In the deﬁbrotide trial, complete response by day
100 was achieved in 23.5% of the deﬁbrotide-treated patients
and 9.4% of the historical controls (P¼0.013), which equated
to an NNT of 7 (1/(0.235-0.094)) to achieve one complete
response 100 days post-HSCT. Day 100 survival was 38.2% in
the deﬁbrotide group and 25.0% in the historical control
group (P¼0.034). Therefore, the NNT to prevent one death in
this study was 8 (1/(0.382-0.25)). To compare the NNTs in
this analysis with those in other studies, a literature searchwas conducted, identifying recent clinical trials in acute
conditions with high short-term mortality. NNTs calculated
from that review ranged from 1 to 59.
Conclusion: The results of this pivotal Phase 3 trial showed
improved complete response and survival in deﬁbrotide-
treated patients compared to historical controls who did not
receive deﬁbrotide for the treatment of severe VOD. The
number needed to treat to achieve this beneﬁt proved either
comparable to or lower than the NNT obtained for other
widely accepted and approved therapeutic medical in-
terventions in critical care.
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Background: Human metapneumovirus (HMPV) is a respi-
ratory virus that was ﬁrst identiﬁed in 2001. In immuno-
compromised hosts, HMPV upper respiratory tract infection
(URI) can progress to lower respiratory tract disease (LRD).
The mortality rate after HMPV LRD in hematopoietic cell
transplant (HCT) recipients is as high as 40%, similar to that of
respiratory syncytial virus, a structurally similar respiratory
virus. To date, most studies in HCT recipients are of very
small sample size, and minimal data exists on risk factors for
LRD. Here we analyzed the seasonality of HMPV infections as
well as patient, transplant and viral risk factors for progres-
sion to LRD.
Methods: This retrospective cohort study included HCT re-
cipients with HMPV documented by RT-PCR transplanted
between 2004 and 2014 at FHCRC. To detect HMPV, naso-
pharyngeal, bronchoalveolar lavage (BAL) or lung biopsy
samples were tested by quantitative PCR with or without
culture or direct ﬂuorescent antibody staining. LRD was
deﬁned as detection of HMPV in a BAL or biopsy sample with
new pulmonary inﬁltrates. Patients diagnosed with LRD  2
days after URI diagnosis were considered to have progression
